These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 629275)

  • 21. The role of irreversibly sickled cells in reducing the osmotic fragility of red cells in sickle cell anemia.
    Figueiredo MS; Zago MA
    Acta Physiol Pharmacol Latinoam; 1985; 35(1):49-56. PubMed ID: 2932889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of oxygen inhalation on endogenous erythropoietin kinetics, erythropoiesis, and properties of blood cells in sickle-cell anemia.
    Embury SH; Garcia JF; Mohandas N; Pennathur-Das R; Clark MR
    N Engl J Med; 1984 Aug; 311(5):291-5. PubMed ID: 6738642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Irreversibly sickled erythrocytes in sickle cell anemia: a quantitative reappraisal.
    Rodgers GP; Noguchi CT; Schechter AN
    Am J Hematol; 1985 Sep; 20(1):17-23. PubMed ID: 4025318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Red blood cell morphology in sickle cell anemia as determined by image processing analysis: the relationship to painful crises.
    Westerman MP; Bacus JW
    Am J Clin Pathol; 1983 Jun; 79(6):667-72. PubMed ID: 6846257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship of glutathione levels and Heinz body formation to irreversibly sickled cells in sickle cell anemia.
    Wetterstroem N; Brewer GJ; Warth JA; Mitchinson A; Near K
    J Lab Clin Med; 1984 Apr; 103(4):589-96. PubMed ID: 6699474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Irreversibly sickled erythrocytes: a consequence of the heterogeneous distribution of hemoglobin types in sickle-cell anemia.
    Bertles JF; Milner PF
    J Clin Invest; 1968 Aug; 47(8):1731-41. PubMed ID: 5666109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of Ca2+-dependent biochemical changes in the ageing process in normal red cells and in the development of irreversibly sickled cells.
    Allan D; Raval PJ
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(4):499-503. PubMed ID: 2446988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 51Cr and DF32P labeling of human blood cells in leukocyte-rich plasma.
    Kurtz SR; Skrabut EM; Catsimpoolas N; Valeri CR
    Exp Hematol; 1981 Nov; 9(10):957-65. PubMed ID: 7308325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro interactions of 51Cr in human red blood cells and hemolysates.
    Kuehl GV; Harkness DR; Skrabut EM; Bechthold DA; Emerson CP; Valeri CR
    Vox Sang; 1981 Apr; 40(4):260-72. PubMed ID: 7257239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drugs for preventing red blood cell dehydration in people with sickle cell disease.
    Nagalla S; Ballas SK
    Cochrane Database Syst Rev; 2010 Jan; (1):CD003426. PubMed ID: 20091545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of the in vitro formation of dense cells and of irreversibly sickled cells by charybdotoxin, a specific inhibitor of calcium-activated potassium efflux.
    Ohnishi ST; Katagi H; Katagi C
    Biochim Biophys Acta; 1989 Feb; 1010(2):199-203. PubMed ID: 2463852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erythrocyte calcium abnormalities and the clinical severity of sickling disorders.
    Steinberg MH; Eaton JW; Berger E; Coleman MB; Oelshlegel FJ
    Br J Haematol; 1978 Dec; 40(4):533-39. PubMed ID: 728370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Determination of mean erythrocyte life span with diisopropylfluorophosphate-32P(DF32P)].
    Saito H; Sakai M
    Kaku Igaku; 1977 Apr; 14(2):211-5. PubMed ID: 559834
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of sickle cell anemia with hydroxyurea and erythropoietin.
    Goldberg MA; Brugnara C; Dover GJ; Schapira L; Charache S; Bunn HF
    N Engl J Med; 1990 Aug; 323(6):366-72. PubMed ID: 1695325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hemolysis in sickle cell disease as measured by endogenous carbon monoxide production. A preliminary report.
    Solanki DL; McCurdy PR; Cuttitta FF; Schechter GP
    Am J Clin Pathol; 1988 Feb; 89(2):221-5. PubMed ID: 3341281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mathematical analysis of 51Cr-labelled red cell survival curves in congenital haemolytic anaemias.
    Kasfiki AG; Antipas SE; Dimitriou PA; Gritzali FA; Melissinos KG
    Eur J Nucl Med; 1982; 7(4):181-3. PubMed ID: 7075620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 14C cyanate as a tag for red cell survival in normal and uremic man.
    Eschbach JW; Korn D; Finch CA
    J Lab Clin Med; 1977 Apr; 89(4):823-8. PubMed ID: 845482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Partially oxygenated sickled cells: sickle-shaped red cells found in circulating blood of patients with sickle cell disease.
    Asakura T; Mattiello JA; Obata K; Asakura K; Reilly MP; Tomassini N; Schwartz E; Ohene-Frempong K
    Proc Natl Acad Sci U S A; 1994 Dec; 91(26):12589-93. PubMed ID: 7809083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemolysis in sickle cell disease.
    Bensinger TA; Gillette PN
    Arch Intern Med; 1974 Apr; 133(4):624-31. PubMed ID: 4594397
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibition of the in vitro formation of irreversibly sickled cells by cepharanthine.
    Ohnishi ST
    Br J Haematol; 1983 Dec; 55(4):665-71. PubMed ID: 6671086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.